Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Next Previous
Trial Profile

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Everolimus
  • Indications Carcinoma; Renal cell carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Study 205
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 05 Nov 2020 According to an Eisai Co Ltd media release, data from this trial will be presented at the International Kidney Cancer Symposium (IKCS) 2020
    • 07 Oct 2020 Results from exploratory retrospective analysis from study 205, assessing composite biomarker scores to predict progression-free survival and overall survival in patients with metastatic RCC, published in the British Journal of Cancer
    • 31 May 2020 Results, post hoc analysis assessing overall treatment differeces by using quality adjusted time without symptoms of disease or toxicity of treatment methodology, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top